Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis von Axelsson, M., Malmeström, C., Nilsson, S., Haghighi, S., Rosengren, L., Lycke, J.

Volltext

NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS von Novakova, L., Axelsson, M., Malmeström, C., Zetterberg, H., Blennow, K., Svenningsson, A., Lycke, J.

Volltext

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs von Tedeholm, H, Lycke, J, Skoog, B, Lisovskaja, V, Hillert, J, Dahle, C, Fagius, J, Fredrikson, S, Landtblom, A-M, Malmeström, C, Martin, C, Piehl, F, Runmarker, B, Stawiarz, L, Vrethem, M, Nerman, O, Andersen, O

Volltext

The impact of hybrid immunity on immune responses after SARS‐CoV‐2 vaccination in persons with multiple sclerosis treated with disease‐modifying therapies von Rabenstein, Monika, Thomas, Olivia G., Carlin, Giorgia, Khademi, Mohsen, Högelin, Klara Asplund, Malmeström, Clas, Axelsson, Markus, Brandt, Anne Frandsen, Gafvelin, Guro, Grönlund, Hans, Kockum, Ingrid, Piehl, Fredrik, Lycke, Jan, Olsson, Tomas, Hessa, Tara

Volltext

Humoral and cellular immune responses after SARSCoV-2-Vaccination in a Swedish cohort of persons with multiple sclerosis treated with disease modifying therapies von Rabenstein, M., Thomas, O. G., Carlin, G., Hellström, Cecilia, Nilsson, Peter, Khademi, M., Hogelin, K. Asplund, Lycke, J., Malmestrom, C., Axelsson, M., Brandt, A. Frandsen, Gafvelin, G., Gronlund, H., Kockum, I., Piehl, F., Olsson, T., Hessa, T.

Volltext

Neurofilament light in serum for monitoring multiple sclerosis: A new quantitative tool for measuring disease activity and therapeutic response von Novakova, L., Zetterberg, H., Axelsson, M., Sundström, P., Khademi, M., Gunnarsson, Martin, Malmeström, C., Svenningsson, A., Olsson, T., Piehl, F., Blennow, K., Lycke, J.

Volltext

Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis von Mattsson, N, Axelsson, M, Haghighi, S, Malmeström, C, Wu, G, Anckarsäter, R, Sankaranarayanan, S, Andreasson, U, Fredrikson, S, Gundersen, A, Johnsen, L, Fladby, T, Tarkowski, A, Trysberg, E, Wallin, A, Anckarsäter, H, Lycke, J, Andersen, O, Simon, AJ, Blennow, K, Zetterberg, H

Volltext

IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: Implications for their possible immunopathogenic roles von Malmeström, C., Andersson, B.A., Haghighi, S., Lycke, J.

Volltext

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein von Novakova, Lenka, Zetterberg, Henrik, Sundström, Peter, Axelsson, Markus, Khademi, Mohsen, Gunnarsson, Martin, Malmeström, Clas, Svenningsson, Anders, Olsson, Tomas, Piehl, Fredrik, Blennow, Kaj, Lycke, Jan

Volltext

Inflammation-related plasma and CSF biomarkers for sclerosis von Huang, Jesse, Khademi, Mohsen, Fugger, Lars, Lindhe, Orjan, Novakova, Lenka, Axelsson, Markus, Malmestrom, Clas, Constantinescu, Clara, Lycke, Jan, Piehl, Fredrik, Olsson, Tomas, Kockum, Ingrid

Volltext

Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS von MALMESTROM, C, HAGHIGHI, S, ROSENGREN, L, ANDERSEN, O, LYCKE, J

Volltext

Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study von Johnsson, M, Stenberg, YT, Farman, HH, Blennow, K, Zetterberg, H, Malmeström, C, Sandgren, S, Rosenstein, I, Lycke, J, Axelsson, M, Novakova, L

Volltext

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients von Alping, Peter, Frisell, Thomas, Novakova, Lenka, Islam-Jakobsson, Protik, Salzer, Jonatan, Björck, Anna, Axelsson, Markus, Malmeström, Clas, Fink, Katharina, Lycke, Jan, Svenningsson, Anders, Piehl, Fredrik

Volltext

Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing‐remitting multiple sclerosis von Novakova, Lenka, Axelsson, Markus, Khademi, Mohsen, Zetterberg, Henrik, Blennow, Kaj, Malmeström, Clas, Piehl, Fredrik, Olsson, Tomas, Lycke, Jan

Volltext

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis von Novakova, Lenka, Axelsson, Markus, Khademi, Mohsen, Zetterberg, Henrik, Blennow, Kaj, Malmeström, Clas, Piehl, Fredrik, Olsson, Tomas, Lycke, Jan

Volltext

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab von Gunnarsson, Martin, Malmeström, Clas, Axelsson, Markus, Sundström, Peter, Dahle, Charlotte, Vrethem, Magnus, Olsson, Tomas, Piehl, Fredrik, Norgren, Niklas, Rosengren, Lars, Svenningsson, Anders, Lycke, Jan

Volltext

Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome von Disanto, Giulio, Adiutori, Rocco, Dobson, Ruth, Martinelli, Vittorio, Dalla Costa, Gloria, Runia, Tessel, Evdoshenko, Evgeniy, Thouvenot, Eric, Trojano, Maria, Norgren, Niklas, Teunissen, Charlotte, Kappos, Ludwig, Giovannoni, Gavin, Kuhle, Jens

Volltext

Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis von Constantinescu, R., Krýsl, D., Bergquist, F., Andrén, K., Malmeström, C., Asztély, F., Axelsson, M., Menachem, E. B., Blennow, K., Rosengren, L., Zetterberg, H.

Volltext

Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis von Novakova, Lenka, Axelsson, Markus, Malmeström, Clas, Zetterberg, Henrik, Björkhem, Ingemar, Karrenbauer, Virginija Danylaité, Lycke, Jan

Volltext

Inflammation-related plasma and CSF biomarkers for multiple sclerosis von Huang, Jesse, Khademia, Mohsen, Fugger, Lars, Lindhe, Örjan, Novakova, Lenka, Axelsson, Markus, Malmeström, Clas, Constantinescu, Clara, Lycke, Jan, Piehl, Fredrik, Olsson, Tomas, Kockum, Ingrid

Volltext